期刊
ADVANCES IN THERAPY
卷 31, 期 9, 页码 915-931出版社
SPRINGER
DOI: 10.1007/s12325-014-0149-1
关键词
Autoinjector; Clinically isolated syndrome; Clinical trial; Disease-modifying therapy; Multiple sclerosis; Neurology; Relapsing-remitting; Secondary-progressive; Safety; Tolerability
资金
- Novartis Pharma AG
Interferon (IFN) beta-1b was the first disease-modifying therapy to be approved for the treatment of multiple sclerosis (MS), and over 21 years of follow-up data demonstrate its efficacy and long-term safety profile. Following recent regulatory approvals in the USA and European Union, IFN beta-1b is now one of the seven disease-modifying therapies [intramuscular IFN beta-1a; subcutaneous (SC) IFN beta-1a; IFN beta-1b SC; glatiramer acetate SC; oral dimethyl fumarate; oral teriflunomide; and intravenous alemtuzumab] indicated for first-line use in relapsing-remitting MS. Here we review the clinical trial and follow-up data for IFN beta-1b and discuss factors that clinicians may consider when selecting this treatment, both at first line in early MS, and later in the disease course.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据